GenMark Diagnostics, Inc
GNMK
GNMK was delisted on the 21st of April, 2021.
106 hedge funds and large institutions have $339M invested in GenMark Diagnostics, Inc in 2019 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 45 increasing their positions, 22 reducing their positions, and 14 closing their positions.
105% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 22
14% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 14
0% more funds holding
Funds holding: 106 → 106 (0)
0.46% less ownership
Funds ownership: 92.11% → 91.65% (-0.46%)
8% less capital invested
Capital invested by funds: $369M → $339M (-$29.8M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $49K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$10.4M |
| 2 |
CCM
Cadian Capital Management
New York
|
+$3.44M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
+$2.93M |
| 4 |
Renaissance Technologies
New York
|
+$1.46M |
| 5 |
BlackRock
New York
|
+$1.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.76M |
| 2 |
JP Morgan Chase
New York
|
-$7.31M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$2.81M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.19M |
| 5 |
Russell Investments Group
London,
United Kingdom
|
-$963K |
GNMK Hedge Fund Activity: Q2 2019 in Review
106 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in GenMark Diagnostics, Inc (GNMK) for Q2 2019, worth a combined $339M — down 8.1% from $369M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new GNMK positions and 14 closed out — a net gain of 2 holders — while 45 added to existing stakes and 22 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $10.4M. The largest seller was T. Rowe Price Associates, cutting an estimated $7.76M.
- 106 institutional investors held GenMark Diagnostics, Inc (GNMK) as of Q2 2019, unchanged from Q1 2019.
- Funds reported $339M of GenMark Diagnostics, Inc stock for Q2 2019, down 8.1% quarter-over-quarter.
- 16 funds opened new GenMark Diagnostics, Inc positions in Q2 2019 and 14 closed out, a net change of +2 holders.
- The largest GenMark Diagnostics, Inc buyer in Q2 2019 was Morgan Stanley, an estimated $10.4M added.
- The largest GenMark Diagnostics, Inc seller in Q2 2019 was T. Rowe Price Associates, an estimated $7.76M sold.
Based on aggregated 13F filings for Q2 2019.